SAT0363 A Systematic Literature Review on The Treatment of Skin, Mucosa and Joint Involvement of Behçet's Syndrome Informing The Eular Recommendations for The Management of Behçet's Syndrome

2016 ◽  
Vol 75 (Suppl 2) ◽  
pp. 798.2-798
Author(s):  
P. Leccese ◽  
Y. Ozguler ◽  
R. Christensen ◽  
S.N. Esatoglu ◽  
I. Olivieri ◽  
...  
1990 ◽  
Vol 33 (3) ◽  
pp. 418-425 ◽  
Author(s):  
Bianca A. Lang ◽  
Ronald M. Laxer ◽  
Paul Thorner ◽  
Mark Greenberg ◽  
Earl D. Silverman

1986 ◽  
Vol 25 (3) ◽  
pp. 293-300 ◽  
Author(s):  
Shigeru KOHNO ◽  
Masaki FUJIKAWA ◽  
Tetsuro KANDA ◽  
Sadahiro ASAI ◽  
Masaki HIROTA ◽  
...  

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1563.2-1563
Author(s):  
R. Talarico ◽  
A. Figliomeni ◽  
L. Mione ◽  
A. Parma ◽  
E. Cioffi ◽  
...  

Background:Beside the organ involvement, a number of demographic factors could considerably influence the long-term and short-term outcomes of Behçet’s syndrome (BS): age at disease onset, duration of disease, gender and sex. Younger men patients are more suitable to have a more severe disease, due to an increased frequency both of morbidity and mortality, related to ocular,vascular and neurological involvementObjectives:The primary aims of the study were to evaluate disease activity in a cohort of BS patients consecutively followed in a BS clinic of a tertiary centre and to explore whether there is a correlation between frequency of relapses in the first 3 years of diseases and disease outcomes.Methods:One-hundred and sixty-five patients (91 males and 74 females; mean age 39±9 years, mean disease duration 9±5) with a diagnosis of BS according to the ISG criteria were studied. Disease activity has been evaluated by BDCAF and patients were also categorized in major or minor involvement of BS according or not to the presence of ocular, neurological and vascular involvement in the course of disease The numbers of relapses in the first 3 years from diagnosis were correlated with disease outcome and damage.Results:At time of the evaluation, 47% of BS patients presented an active disease; 69 patients presented muco-cutaneous involvement, 39 ocular disease, 21 joint involvement, 12 neurological impairment and 9 gastro-enteric involvement. Seventy-nine percent of patients presented in the course of the disease a severe BS involvement and the majority was represented by patients characterised by a more frequent relapse in the first 3 years of disease (M/F: 65/48, mean age 43±3 years). Those patients who experienced a more higher number of relapse in the first 3 years compared to the others were also characterised by poor disease outcomes and worse prognosis over time and this correlation was independent by the therapies taken.Conclusion:The high frequency of relapses during the first three years from diagnosis may be considered an important prognostic factor for disease outcome in BS patients, therefore could be taken into account as a useful element to tailor the management, not only according to the type and severity of symptoms and epidemiological factors.Acknowledgments:noneDisclosure of Interests:None declared


Rheumatology ◽  
2020 ◽  
Vol 59 (Supplement_3) ◽  
pp. iii108-iii117
Author(s):  
Omer Karadag ◽  
Ertugrul Cagri Bolek

Abstract Behcet’s syndrome (BS) is a variable vessel vasculitis with heterogeneous clinical features. Skin, mucosa and joint involvement can cause impairment of quality of life but do not cause permanent damage whereas untreated eye, vascular, nervous system and gastrointestinal system involvement can cause serious damage and even death. Management of BS as a multidisciplinary team enables a faster and more accurate diagnosis and well-integrated treatment strategies. Corticosteroids are the mainstay of therapy. Colchicine, AZA, ciclosporin-A, cyclophosphamide, IFN alpha, and tumour necrosis factor alpha inhibitors are other agents used as induction and/or maintenance therapy. Although biologic agents have been increasingly used, there are still unmet needs. Head-to-head comparison studies of some therapeutic options (e.g. TNF inhibitors vs IFN alpha in uveitis) are required. Novel therapeutic agents in the pipeline could change the standard of care for BS in the future


RAED Dergisi ◽  
2017 ◽  
Vol 9 (1-2) ◽  
pp. 43-46
Author(s):  
Veysel Suzan ◽  
Sinem Nihal Esatoğlu ◽  
Serdal Uğurlu ◽  
Emire Seyahi ◽  
Vedat Hamuryudan

2018 ◽  
pp. annrheumdis-2018-213225 ◽  
Author(s):  
Gulen Hatemi ◽  
Robin Christensen ◽  
Dongsik Bang ◽  
Bahram Bodaghi ◽  
Aykut Ferhat Celik ◽  
...  

2016 ◽  
Vol 38 (2) ◽  
pp. 105-110 ◽  
Author(s):  
Kelly Cristine Tarquinio Marinho ◽  
Bruno Vieira Caputo ◽  
Gilberto Araujo Noro-Filho ◽  
Elcio Magdalena Giovani

Rheumatology ◽  
2018 ◽  
Vol 57 (12) ◽  
pp. 2200-2212 ◽  
Author(s):  
Yesim Ozguler ◽  
Pietro Leccese ◽  
Robin Christensen ◽  
Sinem Nihal Esatoglu ◽  
Dongsik Bang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document